Navigation Links
Amarin Corporation Appoints Industry Veteran Paul E. Huff as Chief Commercial Officer
Date:2/2/2011

DUBLIN and MYSTIC, Conn., Feb. 2, 2011 /PRNewswire/ -- Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that Paul E. Huff has joined the Company as Chief Commercial Officer. In this role, Mr. Huff is responsible for driving Amarin's AMR101 commercialization strategy, including all marketing and sales planning and implementation, including product launch activities. He will also provide business development support as Amarin evaluates potential strategic partnerships for the commercialization of AMR101.

Mr. Huff brings more than 25 years of cardiovascular-focused pharmaceutical marketing and sales experience to Amarin, with a special emphasis on marketing lipid-modifying prescription pharmaceuticals. He has held senior-level sales and marketing positions with a number of pharmaceutical and biotechnology companies, including Reliant Pharmaceuticals, where as Vice President of Marketing, he played a pivotal role in the launch and successful commercialization of Lovaza, the leading prescription Omega-3 product for reducing triglycerides, and later was a contributor to activities leading to the sale of Reliant Pharmaceuticals for $1.65 billion. Similarly, at Kos Pharmaceuticals he played an integral role in the launch and successful commercialization of Niaspan, the leading prescription drug for raising HDL cholesterol. Mr. Huff received a B.S. in marketing from the University of Maryland.

"Paul brings a wealth of industry knowledge and commercialization experience to Amarin that will be invaluable as we seek to maximize the commercial value of AMR101," said Joe Zakrzewski, Executive Chairman and Chief Executive Officer of Amarin. "Paul played a key role in the commercialization of Lovaza and Niaspan, two of the most successful lipid products launched in the US market. He knows the li
'/>"/>

SOURCE Amarin Corporation plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Amarin Announces Proposed Public Offering of American Depositary Shares
2. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
3. Pharmos Corporation Reports 2008 Second Quarter Results
4. China Bionanometer Industries Corporation Promotes New Product Beauty Look in China
5. Genaera Corporation Announces Second Quarter Financial Results
6. MannKind Corporation Reports Second Quarter Financial Results
7. [video] David Brown, President and CEO of LifeVantage Corporation, Discusses Record Page Views on WallSt.nets 3-Minute Press Show
8. Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target
9. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
11. Mymetics Corporation Important Shareholders Information Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 2014) – The severe flooding that devastated a wide ... destructive if the bridges, roads and other infrastructure had ... from the University of Colorado Denver. , "People need ... Jimmy Kim, PhD, associate professor of structural engineering at ... and lead author the study. "There is an assumption ...
(Date:10/27/2014)... WORCESTER, Mass. and TORONTO ... Biotechnology Corporation ( www.generex.com ) (OTCQB: GNBT) today ... the immunological response triggered by its novel proprietary ... of relapse in breast cancer patients. The AE37 ... wholly-owned subsidiary, Antigen Express, Inc. ( www.antigenexpress.com ). ...
(Date:10/27/2014)... Florida (PRWEB) October 27, 2014 ... at reducing and eliminating several types of pediatric ... not been achieved in over 30 years of ... Noah's Light Foundation, proves that one mom's determination ... diagnosed just before Halloween trick-or-treating, and it’s only ...
(Date:10/27/2014)... , October 27, 2014 Investor-Edge ... Inc. (NASDAQ: NBIX ), Insmed Inc. (NASDAQ: ... BCRX ), Dyax Corporation (NASDAQ: DYAX ... these five companies can be accessed at: http://investor-edge.com/register ... NASDAQ Composite ended at 4,483.72, up 0.69%, the Dow ...
Breaking Biology Technology:CU Denver study says upgrading infrastructure could reduce flood damage 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 4FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 2FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 3Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 2Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 3Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 4Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 5
... As the Office of Naval Research (ONR) increases its ... number of hurdles need to be overcome including autonomy ... an Aug. 18 conference on unmanned systems. "We ... for the Navy and Marine Corps," said Dr. Larry ...
... developed new nano-structured glass, turning it into new type ... and will significantly reduce the cost of medical imaging. ... converter created by femtosecond laser nanostructuring of glass published ... by Professor Peter Kazansky at the University,s Optoelectronics Research ...
... Aug. 18, 2011 CBI is pleased to announce ... and Post-Approval Studies Congress, being held September 20-22, 2011 ... an impressive speaker lineup from Celgene, Covidien, FDA, Forest, ... more. Attendees have the opportunity to ...
Cached Biology Technology:Office of Naval Research taking on challenges of unmanned underwater vehicles 2New nanostructured glass for imaging and recording 2FDA, NIH to Speak at CBI's 14th Annual Registries and Post-Approval Studies Congress 2
(Date:10/28/2014)... tragic realities of cancer is that the drugs ... their effectiveness varies unpredictably from patient to patient. ... change this reality by rapidly assessing how effective ... cancer before chemotherapy begins. , A team of ... Professor Melissa Skala has developed the technique, which ...
(Date:10/28/2014)... Researchers from the National University of Singapore (NUS) have ... - breeding and laying direct developing eggs in live ... the white spotted bush frog ( Raorchestes chalazodes ... of two species known to adopt this novel reproductive ... of London,s Biological Journal of the Linnean Society ...
(Date:10/27/2014)... University researchers have delivered a scientific one-two punch with ... fibers self-assemble via their sticky ends. , Collagen is ... of bone and the fibrous tissues that support cells ... to better synthetic collagen for tissue engineering and cosmetic ... Hartgerink has been studying synthetic collagen for a decade, ...
Breaking Biology News(10 mins):Improving breast cancer chemo by testing patient's tumors in a dish 2Improving breast cancer chemo by testing patient's tumors in a dish 3NUS researchers discover for the first time that a rare bush frog breeds in bamboo 2NUS researchers discover for the first time that a rare bush frog breeds in bamboo 3'Sticky' ends start synthetic collagen growth 2'Sticky' ends start synthetic collagen growth 3
... team of French and German researchers report in the ... http://www.fasebj.org ) that people with limb-girdle muscular dystrophy are ... to prevent the loss of muscle tissue. By targeting ... protein, scientists could develop new drugs to stop muscle ...
... thing could be harmful to the environment. For years, ... bacteria and, recently, have used this knowledge to create ... Missouri researcher has found that silver nanoparticles also may ... from wastewater treatment systems. The study was funded by ...
... and Canadian scientists expect to begin trials next month (May) ... of energy trapped in the world,s unrecoverable heavy oil deposits. ... because the oil has become either solid or too thick ... conventional means. , However, scientists at Newcastle University, England, and ...
Cached Biology News:Researchers discover molecular basis of a form of muscular dystrophy 2Too much technology may be killing beneficial bacteria 2Scientists aim to boost world energy supplies -- with microbes! 2Scientists aim to boost world energy supplies -- with microbes! 3Scientists aim to boost world energy supplies -- with microbes! 4